Microbot Medical Inc. Announces Updated At-the-Market Offering Program
Microbot Medical Inc. (NASDAQ: MBOT) has filed a Current Report on Form 8-K, dated April 10, 2026, announcing a key update to its “at the market offering” (ATM) program. This program enables the company to raise capital by selling shares of its common stock directly into the open market at prevailing market prices. Below are the key points and important details for shareholders and investors to consider.
Key Highlights from the Report
-
Expansion of ATM Program:
The company, through an agreement with H.C. Wainwright & Co., LLC, may now offer and sell up to \$39,230,691 worth of its common stock (the “ATM Shares”) from time to time. This is executed under the previously established At the Market Offering Agreement, which was originally dated June 10, 2021, and recently amended on July 1, 2024.
-
Sales Mechanism:
The ATM Shares can be sold in transactions classified as “at the market offerings” under SEC Rule 415, meaning shares may be sold directly on or through the Nasdaq Capital Market, to or through market makers, or directly to Wainwright as principal. Sales can occur at the prevailing market price or through negotiated transactions.
-
Regulatory Compliance:
The shares will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-275634). A prospectus supplement will be filed with the SEC in relation to this offering, ensuring compliance with all regulatory requirements.
-
Legal Opinion:
The validity of the shares under the ATM Program has been confirmed by the Company’s counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Their legal opinion, filed as Exhibit 5.1 to the Form 8-K, affirms that shares issued under this program will be “duly and validly issued, fully paid and non-assessable.”
-
Important Disclosures:
The filing stresses that this Current Report on Form 8-K does not constitute an offer to sell or a solicitation of an offer to buy shares in any jurisdiction where such an action would be unlawful. Sales are only made through the accompanying prospectus and supplement.
What Shareholders Need to Know (Price-Sensitive Items)
-
Potential Dilution:
The ability to sell up to nearly \$40 million worth of common stock could result in dilution for existing shareholders if and when shares are issued. This is a key factor that can impact the share price, especially if large volumes are sold into the open market.
-
Flexible Capital Raising:
The ATM program grants the company flexibility to raise capital opportunistically, which may be used for operational growth, R&D, or other corporate purposes. Investors should consider how these potential new funds could drive the company’s strategic initiatives.
-
Market Impact:
Because shares may be sold directly into the market at prevailing prices, significant sales activity could exert downward pressure on the share price in the short term, depending on investor demand and overall trading volumes.
-
Regulatory and Legal Compliance:
The company is fully compliant with SEC regulations for this offering, minimizing legal risks related to the capital raise.
Exhibits and References
Company and Security Information
- Name: Microbot Medical Inc.
- State of Incorporation: Delaware
- Trading Symbol: MBOT
- Exchange: NASDAQ Capital Market
- Form Type: 8-K (Current Report)
- File Number: 000-19871
- Emerging Growth Company: No (as defined by SEC rules)
Conclusion
The expansion and amendment of Microbot Medical’s ATM facility is a significant corporate action that could influence the company’s funding flexibility and share price. Investors should monitor future filings and sales activity under this program, as any substantial issuance of new shares could impact market dynamics and existing shareholder value.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. The author is not responsible for any losses arising from reliance on this information.
View Microbot Medical Inc. Historical chart here
